<DOC>
	<DOC>NCT01070433</DOC>
	<brief_summary>The objective of this study is to evaluate the safety and efficacy of MEBO in the treatment of subjects with diabetic foot ulcers (DFUs).</brief_summary>
	<brief_title>A Clinical Study of the Safety and Efficacy of MEBO Wound Ointment in Subjects With Diabetic Foot Ulcers</brief_title>
	<detailed_description>This is a phase II, randomized, controlled, multi-center study designed to assess the safety and efficacy of MEBO in the treatment of subjects with DFUs. Subjects meeting entry criteria will be randomly assigned in a 1:1 ratio for up to 8 weeks of treatment with either MEBO or SOC.</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>Male or female ≥18 years of age Able and willing to provide informed consent Able and willing to comply with protocol visits and procedures Target ulcer duration of ≥4 weeks Ulcer of a nondiabetic pathophysiology Known or suspected allergies to any of the components of MEBO Malignancy on target ulcer foot Noncompliance in the screening or runin period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Diabetic Foot Ulcers (DFUs)</keyword>
</DOC>